Genetic features of pulmonary adenocarcinoma presenting with ground-glass nodules: the differences between nodules with and without growth von Kobayashi, Y., Mitsudomi, T., Sakao, Y., Yatabe, Y.

Volltext

Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment von Haratani, K., Hayashi, H., Tanaka, T., Kaneda, H., Togashi, Y., Sakai, K., Hayashi, K., Tomida, S., Chiba, Y., Yonesaka, K., Nonagase, Y., Takahama, T., Tanizaki, J., Tanaka, K., Yoshida, T., Tanimura, K., Takeda, M., Yoshioka, H., Ishida, T., Mitsudomi, T., Nishio, K., Nakagawa, K.

Volltext

An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting von Goto, K., Satouchi, M., Ishii, G., Nishio, K., Hagiwara, K., Mitsudomi, T., Whiteley, J., Donald, E., McCormack, R., Todo, T.

Volltext

Testing for COVID-19 in lung cancer patients von Passaro, A., Peters, S., Mok, T.S.K., Attili, I., Mitsudomi, T., de Marinis, F.

Volltext

Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO an... von Wu, Y.-L., Planchard, D., Lu, S., Sun, H., Yamamoto, N., Kim, D.-W., Tan, D.S.W., Yang, J.C.-H., Azrif, M., Mitsudomi, T., Park, K., Soo, R.A., Chang, J.W.C., Alip, A., Peters, S., Douillard, J.-Y.

Volltext

CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials von Goss, G., Tsai, C.-M., Shepherd, F.A., Ahn, M.-J., Bazhenova, L., Crinò, L., de Marinis, F., Felip, E., Morabito, A., Hodge, R., Cantarini, M., Johnson, M., Mitsudomi, T., Jänne, P.A., Yang, J.C.-H.

Volltext

Surgical implications of the new IASLC/ ATS/ERS adenocarcinoma classification von VAN SCHIL, P. E, ASAMURA, H, RUSCH, V. W, MITSUDOMI, T, TSUBOI, M, BRAMBILIA, E, TRAVIS, W. D

Volltext

Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage II... von Yoshioka, H., Shimokawa, M., Seto, T., Morita, S., Yatabe, Y., Okamoto, I., Tsurutani, J., Satouchi, M., Hirashima, T., Atagi, S., Shibata, K., Saito, H., Toyooka, S., Yamamoto, N., Nakagawa, K., Mitsudomi, T.

Volltext

ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer von Passaro, A., Leighl, N., Blackhall, F., Popat, S., Kerr, K., Ahn, M.J., Arcila, M.E., Arrieta, O., Planchard, D., de Marinis, F., Dingemans, A.M., Dziadziuszko, R., Faivre-Finn, C., Feldman, J., Felip, E., Curigliano, G., Herbst, R., Jänne, P.A., John, T., Mitsudomi, T., Mok, T., Normanno, N., Paz-Ares, L., Ramalingam, S., Sequist, L., Vansteenkiste, J., Wistuba, I.I., Wolf, J., Wu, Y.L., Yang, S.R., Yang, J.C.H., Yatabe, Y., Pentheroudakis, G., Peters, S.

Volltext

Clinical application of amplicon-based next-generation sequencing to therapeutic decision making in lung cancer von Takeda, M., Sakai, K., Terashima, M., Kaneda, H., Hayashi, H., Tanaka, K., Okamoto, K., Takahama, T., Yoshida, T., Iwasa, T., Shimizu, T., Nonagase, Y., Kudo, K., Tomida, S., Mitsudomi, T., Saigo, K., Ito, A., Nakagawa, K., Nishio, K.

Volltext

S-1 as an option for second-line treatment of NSCLC. Is the ‘East Side Story’ applicable in the West? von Hayashi, H., Mitsudomi, T.

Volltext

LBA2_PR Osimertinib (AZD9291) in pre-treated pts with T790M-positive advanced NSCLC: updated Phase 1 (P1) and pooled Phase 2 (P2) results von Yang, J., Ramalingam, S.S., Janne, P.A., Cantarini, M., Mitsudomi, T.

Volltext

Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer? von URAMOTO, H, MITSUDOMI, T

Volltext

A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage... von Yoshioka, H., Azuma, K., Yamamoto, N., Takahashi, T., Nishio, M., Katakami, N., Ahn, M.J., Hirashima, T., Maemondo, M., Kim, S.W., Kurosaki, M., Akinaga, S., Park, K., Tsai, C.M., Tamura, T., Mitsudomi, T., Nakagawa, K.

Volltext

Consensus for HER2 alterations testing in non-small-cell lung cancer von Ren, S., Wang, J., Ying, J., Mitsudomi, T., Lee, D.H., Wang, Z., Chu, Q., Mack, P.C., Cheng, Y., Duan, J., Fan, Y., Han, B., Hui, Z., Liu, A., Liu, J., Lu, Y., Ma, Z., Shi, M., Shu, Y., Song, Q., Song, X., Song, Y., Wang, C., Wang, X., Wang, Z., Xu, Y., Yao, Y., Zhang, L., Zhao, M., Zhu, B., Zhang, J., Zhou, C., Hirsch, F.R.

Volltext

39IN BEYOND EGFR, KRAS, ALK; WHAT ELSE? von Mitsudomi, T

Volltext

Prognostic Significance of p53 Alterations in Patients with Non-Small Cell Lung Cancer: A Meta-Analysis von MITSUDOMI, T, HAMAJIMA, N, OGAWA, M, TAKAHASHI, T

Volltext

Disproportionate representation of KRAS gene mutation in atypical adenomatous hyperplasia, but even distribution of EGFR gene mutation from preinvasive to invasive adenocarcinomas von Sakamoto, H, Shimizu, J, Horio, Y, Ueda, R, Takahashi, T, Mitsudomi, T, Yatabe, Y

Volltext

ES28.01 Biology of KRAS Targeting Agents von Mitsudomi, T.

Volltext

Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer... von Hotta, K., Hida, T., Nokihara, H., Morise, M., Kim, Y.H., Azuma, K., Seto, T., Takiguchi, Y., Nishio, M., Yoshioka, H., Kumagai, T., Watanabe, S., Goto, K., Satouchi, M., Kozuki, T., Shukuya, T., Nakagawa, K., Mitsudomi, T., Yamamoto, N., Asakawa, T., Yoshimoto, T., Takata, S., Tamura, T.

Volltext